Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$4.81 ▲ +0.00
(0.00%)
MKT CAP: $66.9M • VOL: 8.4K
52W L $5 52W H $8
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$4
MEDIAN
$5
MEAN
$5
HIGH
$7
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CSBR TAPE
CSBR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $5.82 | $5.53 | 2025-02-14 | $4.38 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $6.06 | $5.68 | 2025-02-06 | $4.52 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $5.48 | $5.29 | 2025-01-29 | $4.62 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $4.91 | — | 2025-01-17 | $4.71 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $4.23 | $4.57 | 2025-01-09 | $4.28 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $5.72 | $5.00 | 2024-12-18 | $4.18 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $4.67 | $4.86 | 2024-12-04 | $4.47 | -4.3% | 48% | C |